Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDX NASDAQ:LNTH NASDAQ:VIVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$38.37$32.31$19.72▼$39.16$3.01B0.91.25 million shs876,731 shsLNTHLantheus$109.89$98.00$47.25▼$111.86$7.15B-0.06949,110 shs511,083 shsVIVOVivoPower PLC Ordinary Shares$4.68$4.68$1.20▼$8.63$58.63M-0.751.56 million shs1.03 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics+4.32%+12.56%+32.77%+23.54%+73.54%LNTHLantheus+0.85%+0.81%+14.11%+44.40%+38.02%VIVOVivoPower PLC Ordinary Shares-5.65%-16.58%-26.42%+467,999,900.00%+467,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$38.37$32.31$19.72▼$39.16$3.01B0.91.25 million shs876,731 shsLNTHLantheus$109.89$98.00$47.25▼$111.86$7.15B-0.06949,110 shs511,083 shsVIVOVivoPower PLC Ordinary Shares$4.68$4.68$1.20▼$8.63$58.63M-0.751.56 million shs1.03 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics+4.32%+12.56%+32.77%+23.54%+73.54%LNTHLantheus+0.85%+0.81%+14.11%+44.40%+38.02%VIVOVivoPower PLC Ordinary Shares-5.65%-16.58%-26.42%+467,999,900.00%+467,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.82Moderate Buy$49.3028.49% UpsideLNTHLantheus 2.73Moderate Buy$101.86-7.31% DownsideVIVOVivoPower PLC Ordinary Shares 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CLDX, VIVO, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026LNTHLantheus Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$115.006/23/2026VIVOVivoPower PLC Ordinary Shares Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/15/2026CLDXCelldex Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.006/10/2026CLDXCelldex Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $45.006/4/2026VIVOVivoPower PLC Ordinary Shares Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/27/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$100.00 ➝ $115.005/26/2026LNTHLantheus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/13/2026CLDXCelldex Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$38.00 ➝ $54.005/11/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$98.00 ➝ $115.005/8/2026LNTHLantheus CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/8/2026CLDXCelldex Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$45.00 ➝ $48.00(Data available from 7/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$865K3,481.78N/AN/A$7.93 per share4.84LNTHLantheus$1.54B4.64$6.44 per share17.06$16.43 per share6.69VIVOVivoPower PLC Ordinary Shares$61K961.09N/AN/A$1.60 per share2.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$258.76M-$4.26N/AN/AN/AN/A-50.72%-46.59%8/6/2026 (Estimated)LNTHLantheus$233.56M$4.1526.4820.43N/A18.05%29.32%15.00%8/5/2026 (Estimated)VIVOVivoPower PLC Ordinary Shares-$12.79MN/AN/AN/AN/AN/AN/AN/AN/ALatest CLDX, VIVO, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/26/2026Q2 2026VIVOVivoPower PLC Ordinary SharesN/A-$0.2970N/A-$0.2970N/A$0.01 million5/7/2026Q1 2026CLDXCelldex Therapeutics-$1.1472-$1.18-$0.0328-$1.18$0.80 million$0.02 million5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/AVIVOVivoPower PLC Ordinary Shares$0.5010.68%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A8.928.92LNTHLantheus0.472.832.64VIVOVivoPower PLC Ordinary SharesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/ALNTHLantheus99.06%VIVOVivoPower PLC Ordinary Shares15.80%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics5.20%LNTHLantheus1.70%VIVOVivoPower PLC Ordinary Shares2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15078.49 million74.41 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableVIVOVivoPower PLC Ordinary Shares4112.53 million12.24 millionN/ALNTH, CLDX, and VIVO HeadlinesRecent News About These CompaniesVivoPower sharpens AI data center focus, updates separation plans for two units2 hours ago | proactiveinvestors.comVivoPower Reinforces Focus on AI Data Center Business and Provides Update on Non-Core BusinessesJuly 2 at 5:25 PM | globenewswire.comVivoPower PLC Class AJune 30 at 7:19 AM | cnn.comVivoPower PLC. - Ordinary Shares - Class AJune 29, 2026 | money.usnews.comVivoPower selects preferred tenant for Norway AI data centerJune 29, 2026 | proactiveinvestors.comCorrection: VivoPower Selects Global AI Industry Leader as Preferred Tenant for Lease of Norway Operational Data CenterJune 29, 2026 | globenewswire.comVivoPower Selects Global AI Industry Leader as Preferred AI Tenant for Lease of Norway Operational Data CenterJune 29, 2026 | globenewswire.comVivoPower PLC.June 17, 2026 | money.usnews.comVivoPower extends B Corp status to 2028June 16, 2026 | proactiveinvestors.comVivoPower extends B Corp status to 2028June 16, 2026 | proactiveinvestors.comVivoPower's B Corporation Recertification Strengthens Its Sovereign Infrastructure Mandate; Tembo Qualified to Use B Corp LogoJune 16, 2026 | globenewswire.comVivoPower taps ex-SpaceX battery engineer for AI data center advisory roleJune 2, 2026 | proactiveinvestors.comVivoPower Appoints SpaceX Veteran Porter Harris to Support AI Data Center Power and Battery Storage StrategyJune 2, 2026 | globenewswire.comVivoPower shortlists AI operator tenants for Norwegian data centerMay 21, 2026 | proactiveinvestors.comVivoPower Shortlists AI Tenants for 41.5MW Norway AI Data Center After Receiving Multiple BidsMay 21, 2026 | globenewswire.comVivoPower PLCMay 17, 2026 | edition.cnn.comVivoPower to join KBRA panel on AI infrastructure and data center capital marketsMay 14, 2026 | proactiveinvestors.comVivoPower CIO to Address Power Access and AI Infrastructure Financing at KBRA's European Data Centers Event in LondonMay 14, 2026 | globenewswire.comVivoPower to Present at the Emerging Growth ConferenceApril 29, 2026 | globenewswire.comVivoPower secures $1.9M EBITDA boost From Norway grid flexibility marketsApril 27, 2026 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLNTH, CLDX, and VIVO Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$38.37 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$38.32 -0.05 (-0.14%) As of 07/2/2026 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Lantheus NASDAQ:LNTH$109.89 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$111.54 +1.65 (+1.50%) As of 07/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.VivoPower PLC Ordinary Shares NASDAQ:VIVO$4.68 0.00 (0.00%) As of 07/2/2026 04:00 PM EasternVivoPower PLC is engaged in building, owning, and leasing powered land and data center infrastructure for AI compute applications. The group delivers specialized infrastructure solutions across the AI Data Centers, Power-to-X, and Electric Mobility. It is develop and operated infrastructure that enables sovereign nations and institutional partners to secure control over power, data, and national intelligence, supporting AI, compute-intensive workloads, and energy transition use cases. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play Why Kroger's Giant Eagle Deal Could Change Everything SMRs Spark a Chain Reaction for Nano Nuclear 3 Dividend ETFs Built for Stability in a Volatile Market Agility Robotics’ SPAC Deal Opens a Rare Door Into Humanoid AI Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
